450 published test results across 93 vendors · latest: 12 Oct 2026
| # | Vendor | Tests | Price/mg | Score |
|---|---|---|---|---|
| 1 | PPeptide Partners | 10 | $3.24 | 86 |
| 2 | YYimei Unverified | 8 | $1.14 | 83 |
| 3 | RReta-Peptide | 16 | $0.72 | 82 |
| 4 | SShanghai Sigma Audley SSA Unverified | 8 | — | 81 |
| 5 | SShenzhen Loga Tech LG LOGA Unverified | 6 | $0.80 | 79 |
| 6 | ZZhejiang Yichenkang Biotechnology Unverified | 7 | $0.70 | 77 |
| 7 | HHXNet Unverified | 5 | — | 77 |
| 8 | MMai Peptide Unverified | 8 | $0.90 | 77 |
| 9 | PPeptide Sciences | 9 | $8.80 | 76 |
| 10 | SShandong Aishi Biotechnology Unverified | 4 | $1.96 | 76 |
Computed from publicly published third-party results. How scoring works · every listing is free and un-buyable. Vendors marked Unverified appear for their published results but are left out of the vendor rankings.
Ipamorelin is the modern default among growth hormone secretagogues, prized for stimulating GH with minimal effect on cortisol, prolactin, or appetite. Selectivity, not raw potency, is its selling point, and the reason it anchors most GH stacks.
The record here is solid but not spectacular: 347 published tests across 61 vendors, with the leaders scoring 81 to 84 on eight to sixteen tests each and dates running through August 2026. Where buyers get burned is price. Among just the top five vendors, published pricing spans $0.72 to $3.74 per milligram, a five-fold difference between sellers with nearly identical scores. Purity does not explain that spread; retail positioning does.
Verified vendors sell ipamorelin between roughly $0.72 and $3.74 per milligram as of September 2026, and the score difference across that range is a few points at most. Run the per-mg math on tested content before comparing anything else; the calculator handles the rest of the arithmetic once a vial arrives.
No. It was developed as a drug candidate in the 1990s and never completed development. Everything sold today is research-chemical production.
Forum protocols combine a GHRH analog with a secretagogue on the theory that the two mechanisms amplify each other. Whatever the merits of the theory, the CJC-1295 testing record is much weaker than ipamorelin’s, so the stack’s label risk is concentrated in that second vial.
Top-vendor records run through August 2026, with most leaders tested inside the last six months. Check the last-tested column above before ordering; the aggregate number hides per-vendor gaps.
Nothing on this page is medical advice; compounds shown are sold for research purposes only. Data is aggregated from publicly published third-party results and traces to its source.